Concern-driven safety assessment of nanomaterials: An integrated approach using material properties, hazard, biokinetic, and exposure data and considerations on grouping and read-across

Safety of Nanomaterials along Their Lifecycle: Release, Exposure, and Human Hazards

Volumn , Issue , 2014, Pages 357-380

  Oomen, Agnes ^a   Bos, Peter ^a   Landsiedel, Robert ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b BASF SE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOHAZARDS; NANOSTRUCTURED MATERIALS;

ASSESSMENT APPROACHES; BIOLOGICAL EFFECTS; EXPOSURE ASSESSMENT; HAZARD IDENTIFICATION; INTEGRATED APPROACH; PHYSICOCHEMICAL CHARACTERISTICS; PRIMARY PARTICLES; SAFETY ASSESSMENTS;

RISK ASSESSMENT;

EID: 85043094772     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b17774     Document Type: Chapter

References (78)

1. Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, Russom CL, Schmieder PK, Serrrano JA, Tietge JE, Villeneuve DL. (2010). Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Env Toxicol Chem 29:730–741.
2. Anon (2006). Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. O.J. L 396/1, 30 December 2006.
3. Anon (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. O.J. L 276/33, 20 October 2010.
4. Anon. (2011). Commission recommendation on the definition of nanomaterial. OJ L 275/38, 18 October 2011.
5. Card JW, Magnuson BA. (2010). A method to assess the quality of studies that examine the toxicity of engineered nanomaterials. Int J Toxicol 29:402–410.
6. Castranova V, Schulte PA, Zumwalde RD. (2012). Occupational Nanosafety Considerations for Carbon Nanotubes and Carbon Nanofibers. AccChem Res 5 December 2012, epub ahead of print.
7. Combes, R, Balls M. (2005). Intelligent testing strategies for chemicals testing–a case of more haste, less speed? ATLA 33:289–297.
8. Combes R, Barratt M, Balls M. (2003). An overall strategy for the testing of chemicals for human hazard and risk assessment under the EU REACH system. ATLA 31:7–19.
9. CTTAEA, NRC. (2007). Committee on Toxicity Testing and Assessment of Environmental Agents, US National Research Council. Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academics Press, 216 pp. http://www.nap.edu/catalog.php?record_id=11970#toc.
10. Damoiseaux R, George S, Li M, Pokhrel S, Ji Z, France B, Xia T, Suarez E, Rallo R, Mädler L, Cohen Y, Hoek EMV, Nel AE. (2011). No time to lose—high throughput screening to assess nanomaterial safety. Nanoscale 3:1345–1360.
11. Dan M, Wu P, Grulke EA, Graham UM, Unrine JM, Yokel RA. (2012). Ceria engineered nanomaterial distribution in and clearance from blood: size matters. Nanomed 7:95–110.
12. ECHA. (2008). Guidance on information requirements and chemical safety assessment. Chapter R.6. QSARs and grouping of chemicals. European Chemicals Agency. 134 pp.; availableat:http://echa.europa.eu/documents/10162/13632/information_requirements_r6_en.pdf.
13. ECHA. (2010). Practical guide 4: How to report data waiving. European Chemicals Agency ECHA-10-B-09-EN, 24 March 2010. 19 pp.; available at: http://echa.europa.eu/documents/10162/13655/pg_report_data_waiving_en.pdf.
14. ECHA. (2012a). Guidance on information requirements and chemical safety assessment. Appendix R7-1 Recommendations for nanomaterials applicable to Chapter R7a Endpoint specific guidance. European Chemicals Agency ECHA-12-G-03-EN, April 2012. 60 pp.; available at:http://echa.europa.eu/documents/10162/13632/appendix_r7a_nanomaterials_en.pdf.
15. ECHA. (2012b). Background Paper. An introduction to the assessment of read across. European Chemicals Agency. 8pp.; available at:http://echa.europa.eu/documents/10162/5649897/ws_raa_20121003_background_paper_an_introduction_to_the_assessment_of_read-across_in_echa_en.pdf.
16. ECHA. (2012c). Assessment of read-across in REACH. European Chemicals Agency. 58pp.; available at:http://echa.europa.eu/documents/10162/5649897/ws_raa_20121003_assessment_of_read-across_in_echa_de_raat_en.pdf.
17. ECHA. (2013). Grouping of substances and read-across approach. Part I. Introductory note. European Chemicals Agency ECHA-13-R-02-EN. 11 pp.; availableat:http://echa.europa.eu/documents/10162/13628/read_across_introductory_note_en.pdf.
18. Gasser M, Rothen-Rutishauser B, Krug HF, Gehr P, Nelle M, Yan B, Wick P. (2010). Lipids of the pulmonary surfactant and functional groups on multi-walled carbon nanotubes influence blood plasma proteins adsorption differently. J Nanobiotech 8:31.
19. Gasser M, Wick P, Clift MJ, Blank F, Diener L, Yan B, Gehr P, Krug HF, Rothen-Rutishauser B. (2012). Pulmonary surfactant coating of multi-walled carbon nanotubes (MWCNTs) influences their oxidative and pro-inflammatory potential in vitro. Part Fibre Toxicol 9:17.
20. George S, Xia T, Rallo R, Zhao Y, Ji Z, Lin S, Wang X, Zhang H, France B, Schoenfeld D, Damoiseaux R, Liu R, Lin S, Bradley KA, Cohen Y, Nel AE. (2011). Use of a high-throughput screening approach coupled with in vivo zebrafish embryo screening to develop hazard ranking for engineered nanomaterials. ACS nano 5:1805–1817.
21. German Competent Authorities, (2011). Nanomaterials and REACH. Background paper on the position of German competent authorities. 52 pages; availableat:http://www.reach-clp-helpdesk.de/de/Downloads/Hintergrundpapier%20Nano%20und%20REACH%20engl.%20Version.pdf?__blob=publicationFile.
22. Hankin SM, Peters SAK, Poland CA, Foss Hansen S, Holmqvist J, Ross BL, Varet J, Aitken RJ. (2011). Specific advice on fulfilling information requirements for nanomaterials under REACH (RIP-oN 2)–final project peport. REACH-NANO consultation. RNC/RIP-oN2/FPR/1/FINAL. 356 pp; available at: http://ec.europa.eu/environment/chemicals/nanotech/pdf/report_ripon2.pdf.
23. Hassellov M, Readman J, Rabville J, Tiede K. (2008). Nanoparticle analysis and characterization methodologies in environmental risk assessment of engineered nanoparticles. Ecotoxicol 17:344–361.
24. Hristozov DR, Gottardo S, Cinelli M, Isigonis P, Zabeo A, Critto A, Van Tongeren M, Tran L, Marcomini A. (2013). Application of a quantitative weight of evidence approach for ranking and prioritising occupational exposure scenarios for titanium dioxide and carbon nanomaterials. Nanotoxicol 15 Jan 2013, epub ahead of print. doi:10.3109/17435390.2012.760013.
25. IHCP 2005. REACH and the need for intelligent testing strategies. Institute for Health and Consumer Protection, European Commission, Joint Research Centre EUR 21554 EN.
26. Johnston H, Brown D, Kermanizadeh A, Gubbins E, Stone V. (2012). Investigating the relationship between nanomaterial hazard and physicochemical properties: Informing the exploitation of nanomaterials within therapeutic and diagnostic applications. J Controlled Release 164:307–313.
27. Klein CL, Wiench K, Wiemann M, Ma-Hock L, van Ravenzwaay B, Landsiedel R. (2012). Hazard identification of inhaled nanomaterials: Making use of short-term inhalation studies. Arch Toxicol 86:1137–1151.
28. Kuempel ED, Castranova V, Geraci CL, Schulte PA. (2012). Development of risk-based nanomaterial groups for occupational exposure control. J Nanopart Res 14:1029.
29. Lai ZW, Yan Y, Caruso F, Nice EC. (2012). Emerging techniques in proteomics for probing nano-bio interactions. ACS Nano 6:10438–48.
30. Landsiedel R, Fabian E, Ma-Hock L, Wohlleben W, Wiench K, Oesch F, van Ravenzwaay B. (2012a). Toxico-/biokinetics of nanomaterials. Arch Toxicol 86(7):1021–1060.
31. Landsiedel R, Ma-Hock L, Haussmann HJ, van Ravenzwaay B, Kayser M, Wiench K. (2012b). Inhalation studies for the safety assessment of nanomaterials: Status quo and the way forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol 4(4):399–413.
32. Landsiedel R, Ma-Hock L, Kroll A, Hahn D, Schnekenburger J, Wiench K, Wohlleben W. (2010). Testing metal-oxide nanomaterials for human safety. Adv Mater 22:2601–2627.
33. Lankveld DP, Oomen AG, Krystek P, Neigh A, Troost-de Jong A, Noorlander CW, Van Eijkeren JC, Geertsma RE, De Jong WH. (2010). The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomat 31:8350–8361.
34. Linsinger T, Roebben G, Gilliand D, Calzolai L, Rossi F, Gibson P, Klein CH. (2012).Requirements on measurements for the implementation of the European Commission definition of the term ‘nanomaterial’. JRC publication no JRC73260, ISBN 978-92-79-25603-5; available at: (http://publications.jrc.ec.europa.eu/repository/handle/111111111/26399).
35. Liu J, Legros S, Ma G, Veinot JG, von der Kammer F, Hofmann T. (2012). Influence of surface functionalization and particle size on the aggregation kinetics of engineered nanoparticles. Chemosphere 87:918–924.
36. Liu R, Rallo R, George S, Ji Z, Nair S, Nel AE, Cohen Y. (2011). Classification NanoSAR development for cytotoxicity of metal oxide nanoparticles. Small 7(8):1118–1126.
37. Lövestam G, Rauscher H, Roebben G, Sokull Klüttgen B, Gibson N, Putaud J-P, Stamm H. (2010). Considerations on a definition of nanomaterial for regulatory purposes. JRC Reference Reports. EUR 24403 EN.
38. Lundqvist M, Stigler J, Cedervall T, Berggård T, Flanagan MB, Lynch I, Elia G, Dawson K. (2011). The evolution of the protein corona around nanoparticles: A test study. ACS Nano 5:7503–7509.
39. Ma-Hock L, Burkhardt S, Strauss V, Gamer AO, Wiench K, van Ravenzwaay B, Landsiedel R. (2009). Development of a short-term inhalation test in the rat using nano titanium dioxide as a model substance. Inhal Toxicol 21:102–118.
40. Meng H, Xia T, George S, Nel AE. (2009). A predictive toxicological paradigm for the safety assessment of nanomaterials. ACS nano 3:1620–1627.
41. Nel AE, Mädler L, Velegol D, Xia T, Hoek EMV, Somasundaran P, Klaessig F, Castranova V, Thompson M. (2009). Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8:543–557.
42. Nel AE, Nasser E, Godwin H, Avery D, Bahadori T, Bergeson L, Beryt E, Bonner JC, Boverhof D, Carter J, Castranova V, Deshazo JR, Hussain SM, Kane AB, Klaessig F, Kuempel E, Lafranconi M, Landsiedel R, Malloy T, Miller MB, Morris J, Moss K, Oberdorster G, Pinkerton K, Pleus RC, Shatkin JA, Thomas R, Tolaymat T, Wang A. (2013a) A multi-stakeholder perspective on the use of alternative test strategies for nanomaterial safety assessment. ACS Nano: 7:6422–6433.
43. Nel AE, Xia T, Meng H, Wang X, Lin S, Ji Z, Zhang H. (2013b). Nanomaterial toxicity testing in the 21st century: Use of a predictive toxicological approach and high-throughput screening. Acc Chem Res 46:607–621.
44. Oberdörster G. (2009) Safety assessment for nanotechnology and nanomedicine: Concepts of nanotoxicology. J Int Med 267:89–105.
45. OECD. (2007). Guidance on grouping of chemicals. Series on testing and assessment No. 80. ENV/JM/MONO(2007)28. OECD, Paris, France, 26 September 2007.
46. OECD. (2010). Guidance manual for the testing of manufactured nanomaterials: OECD’s sponsorship programme; first revision. ENV/JM-MONO(2009)20/REV, OECD, Paris, France, 2 June 2010.
47. OECD. (2011). A steering group 7 case-study for hazard identification of inhaled nanomaterials: An integrated approach with short-term inhalation studies. ENV/CHEM/NANO(2011)6/REV1. 10th Meeting of the Working Party on Manufactured Nanomaterials, OECD, Paris, France, 27–29 June 2012.
48. OECD. (2012a). Proposal for a template, and guidance on developing and assessing the completeness of adverse outcome pathways. 17 pp; available at: http://www.oecd.org/env/ehs/testing/49963554.pdf.
49. OECD. (2012b). Appendix I. Collection of working definitions. OECD, Paris, France; available at: http://www.oecd.org/env/ehs/testing/49963576.pdf.
50. OECD. (2013). Revised Draft Recommendation of the Council on the safety testing and assessment of manufactured nanomaterials. ENV/CHEM/NANO(2013)3/REV1 Working Party on Manufactured Nanomaterials. OECD, Paris, France, 25 February 2013.
51. Oomen AG, Bos PMJ, Fernandes TF, Hund-Rinke K, Boraschi D, Byrne HJ, Aschberger K, Gottardo S, van der Kammer F, Kühnel D, Hristozov D, Marcomini A, Migliore L, Scott-Fordsmand J, Wick P, Landsiedel R. (2013). Concern-driven integrated approaches to nanomaterial testing and assessment - Report of the NanoSafety Cluster Working Group 10. Nanotoxicol 28 May 2013, epub ahead of print.
52. Packroff R. (2013). The synergic dimensions of OSH strategy in the context of other EU policies: Nanomaterials …and other advanced materials. Presentation on behalf of the German Federal Institute for Occupational Safety and Health. ETUI Conference: EU Strategy for health and safety and work 2013–2020, Brussels, 27 March 2013; available at: http://www.etui.org/Events/Conference-on-the-European-Health-and-Safety-Strategy-2013–2020.
53. Patlewicz G, Ball N, Booth ED, Hulzebos E, Zvinavashe E, Hennes C. (2013). Use of category approaches, read-across and (Q)SAR: General considerations. Regul Toxicol Pharmacol 67:1–12.
54. Rallo R, France B, Liu R, Nair S, George S, Damoiseaux R, Giralt F, Nel AE, Bradley K, Cohen Y. (2011). Self-organizing map analysis of toxicity-related cell signaling pathways for metal and metal oxide nanoparticles. Env Science Technol 45:1695–1702.
55. Rehn B, Rehn S, Bruch J. (1999). Ein neues in-vitro-Prüfkonzept (Vektorenmodell) zum biologischen Screening und Monitoring der Lungentoxizität von Stäuben. Gefahrstoffe–Reinhaltung der Luft 59:181–188.
56. Rothen-Rutishauser B, Brown DM, Piallier-Boyles M, Kinloch IA, Windle AH, Gehr P, Stone V. (2010). Relating the physicochemical characteristics and dispersion of multiwalled carbon nanotubes in different suspension media to their oxidative reactivity in vitro and inflammation in vivo. Nanotoxicol 4:331–342.
57. Russell WMS, Burch RL. (1959). The principles of humane experimental technique. London, UK. Methuen. Reprinted by UFAW, 1992, 238 pp., 8 Hamilton Close, South Mimms, Potters Bar, Herts EN6 3QD England.
58. Safe SH. (1998). Development validation and problems with the toxic equivalency factor approach for risk assessment of dioxins and related compounds. J AnimSci 76:134–141.
59. Sager TM, Porter DW, Robinson VA, Lindsley WG, Schwegler-Berry DE, Castranova V. (2007). An improved method to disperse nanoparticles for in vitro and in vivo investigation of toxicity. Nanotoxicol 1:118–129.
60. Sauer UG, Vogel S, Aumann A, Strauss V, Dammann M, Treumann S, Wohlleben W, Kolle SN, Gröters S, Wiench K, van Ravenzwaay B, Landsiedel R. (2013). Cytotoxicity, apoptosis, oxidative stress, and inflammation induced by 16 OECD reference nanomaterials in rat precision-cut lung slices. Toxicol Appl Pharmacol in press.
61. SCENIHR. (2009). The Scientific Committee on Emerging and Newly Identified Health Risks Opinion on Risk assessment of products of nanotechnologies. 19 January 2009; available at: http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf.
62. Schleh C, Kreyling WG, Lehr C-M. (2013). Pulmonary surfactant is indispensable in order to simulate the in vivo situation. Part Fibre Toxicol 10:6.
63. Schulze C, Kroll A, Lehr C, Schäfer UF, Becker K, Schnekenburger J, Schulze Isfort C, Landsiedel R, Wohlleben W. (2008). Not ready to use - Overcoming pitfalls when dispersing nanoparticles in physiological media. Nanotoxicol 2(2):51–61.
64. Shvedova AA, Tkach AV, Kisin ER, Khaliullin T, Stanley S, Gutkin DW, Star A, Chen Y, Shurin GV, Kagan VE, Shurin MR. (2013). Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells. Small 9:1691–1695.
65. Som C, Nowack B, Krug HF, Wick P. (2012). Toward the development of decision supporting tools that can be used for safe production and use of nanomaterials. Acc Chem Res 46:863–872.
66. Spielmann H, Sauer UG, Mekenyan O. (2011). A critical evaluation of the 2011 ECHA reports on compliance with the REACH and CLP regulations and on the use of alternatives to testing on animals for compliance with the REACH regulation. ATLA 39, 481–493.
67. Stone V, Nowack B, Baun A, van den Brink N, von der Kammer F, Dusinska M, Handy R, Hankin S, Hassellöv M, Joner E, Fernandes TF. (2010). Nanomaterials for environmental studies: classification, reference material issues, and strategies for physico-chemical characterisation. Sci Total Env 408:1745–1754.
68. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. (2007). Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 95:300–12. (erratum in: Toxicol Sci. 2007. 97:614).
69. Thomas CR, George S, Horst AM, Ji Z, Miller RJ, Peralta-Videa JR, Xia T, Pokhrel S, Mädler L, Gardea-Torresdey JL, Holden PA, Keller AA, Lenihan HS, Nel AE, Zink JI. (2011). Nanomaterials in the environment: From materials to high-throughput screening to organisms. ACS nano 5:13–20.
70. van Leeuwen CJ, Patlewicz GY, Worth AP. (2007). Intelligent Testing Strategies In: van Leeuwen CJ, Vermeire TG, Vermeire T, eds. Risk assessment of chemicals: An introduction, Springer, Heidelberg, Germany, 467–509.
71. Wang X, Xia T, Ntim SA, Ji Z, George S, Meng H, Zhang H, Castranova V, Mitra S, Nel AE. (2010). Quantitative techniques for assessing and controlling the dispersion and biological effects of multiwalled carbon nanotubes in mammalian tissue culture cells. ACS nano 4:7241–7252.
72. Wang X, Xia T, Ntim SA, Ji Z, Lin S, Meng H, Chung CH, George S, Zhang H, Wang M, Li N, Yang Y, Castranova V, Mitra S, Bonner JC, Nel AE. (2011). Dispersal state of multiwalled carbon nanotubes elicits profibrogenic cellular responses that correlate with fibrogenesis biomarkers and fibrosis in the murine lung. ACS nano 5:9772–9787.
73. Wohlleben W. (2012). Validity range of centrifuges for the regulation of nanomaterials: From classification to as-tested coronas. J Nanopart Res 14:1300.
74. Xia T, Kovochich M, Liong M, Zink JI, Nel AE. (2008). Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. ACS Nano. 2:85–96.
75. Xia T, Malasarn D, Lin S, Ji Z, Zhang H, Miller RJ, Keller AA, Nisbet RM, Harthorn BH, Godwin HA, Lenihan HS, Liu, R, Gardea-Torresdey J, Cohen Y, Mädler L, Holden PA, Zink JI, Nel AE. (2012). Implementation of a multidisciplinary approach to solve complex nano EHS problems by the UC Center for the Environmental Implications of Nanotechnology. Small 9:1428–1443.
76. Yanamala N, Kagan VE, Shvedova AA. (2013). Molecular modeling in structural nano-toxicology: Interactions of nano-particles with nano-machinery of cells. Adv Drug Deliv Rev 28 May 2013, epub ahead of print. doi: 10.106/j.addr.2013.05.005.
77. Zhang H, Ji Z, Xia T, Meng H, Low-Kam C, Liu R, Pokhrel S, Lin S, Wang X, Liao Y-P, Wang M, Li L, Rallo R, Damoiseaux R, Telesca D, Mädler L, Cohen Y, Zink JI, Nel AE. (2012). Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. ACS nano 6(5):4349–4368.
78. Zuin S, Micheletti C, Critto A, Pojana G, Johnston H, Stone V, Tran L, Marcomini A. (2011). Weight of evidence approach for the relative hazard ranking of nanomaterials. Nanotoxicol 5:445–458.